BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Glucophage (metformin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Glucophage (metformin)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05532813-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05532813)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Evaluation of the Eff
 icacy and Safety of Metformin in the Myotonic Dystrophy Type 1 (Steinert's
  Disease)\nEstimated primary completion: November 2026. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05532813
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07796191-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07796191)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Drug-drug Interaction
 s Studies of VC005 Tablets in Healthy Adult Subjects\nEstimated primary co
 mpletion: 30 November 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07796191
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02087826-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT02087826)
DESCRIPTION:Glucophage (metformin)\, phase na\, Type 2 Diabetes.\nStudy: St
 udy of Clinical Response to Acute Metformin By Leveraging Evaluations Duri
 ng a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS\nEstima
 ted primary completion: December 2026. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT02087826
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03603912-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT03603912)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Targeting Risk Interv
 entions and Metformin for Atrial Fibrillation (TRIM-AF)\nEstimated primary
  completion: December 2026. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03603912
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05574387-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05574387)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin as Added on
  Therapy in Patients With Ulcerative Colitis\nEstimated primary completion
 : December 2026. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metf
 ormin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT05574387
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687876-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06687876)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin as a Metabo
 lic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neo
 adjuvant Chemoradiotherapy\nEstimated primary completion: December 2026. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06687876
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07093476-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07093476)
DESCRIPTION:Glucophage (metformin)\, phase 3\, Type 2 Diabetes.\nStudy: Eff
 icacy and Safety of Add-On Therapy With Empagliflozin in Patients With Typ
 e 2 Diabetes on a Background of Alogliptin and Metformin\nEstimated primar
 y completion: December 2026. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07093476
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07785934-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07785934)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Phase I Drug-Drug Int
 eraction Study of UBT251 Injection in Participants With Overweight or Obes
 ity\nEstimated primary completion: December 2026. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07785934
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846138-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT06846138)
DESCRIPTION:Glucophage (metformin)\, phase na\, Type 2 Diabetes.\nStudy: En
 hancing the Efficacy and Tolerability of Metformin by add-on Polyherbal Fo
 rmulation: a Gut Microbiome Study\nEstimated primary completion: 1 Decembe
 r 2026. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0684613
 8
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07485777-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07485777)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Comparative Evaluati
 on of Topical 30% Metformin and Kligman's Regimen in Women With Melasma\nE
 stimated primary completion: 1 December 2026. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07485777
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07495748-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07495748)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Comparative Evaluati
 on of Topical Metformin and Topical Tranexamic Acid in Melasma\nEstimated 
 primary completion: 1 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07495748
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07502001-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07502001)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Influence of HDM1005 
 on Gastric Emptying and Pharmacokinetics of Metformin\, Atorvastatin\, War
 farin\, and Digoxin\nEstimated primary completion: 1 December 2026. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT07502001
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07604779-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261203
DTEND;VALUE=DATE:20261204
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07604779)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Enhancing PCOS Manag
 ement for Better Outcomes of Intracytoplasmic Sperm Injection\nEstimated p
 rimary completion: 3 December 2026. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07604779
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07550816-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261205
DTEND;VALUE=DATE:20261206
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07550816)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Drug-drug Interaction
  Study of ZT002 Injection in Overweight and Obese Participants\nEstimated 
 primary completion: 5 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07550816
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03889795-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT03889795)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Phase IB Metformin\, 
 Digoxin\, Simvastatin in Solid Tumors\nEstimated primary completion: 30 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT03
 889795
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05680805-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261230
DTEND;VALUE=DATE:20261231
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT05680805)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Metabolic Responses o
 f Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS\nEstimated p
 rimary completion: 30 December 2026. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05680805
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03006172-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT03006172)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: To Evaluate the Safet
 y\, Tolerability\, and Pharmacokinetics of Inavolisib Single Agent in Part
 icipants With Solid Tumors and in Combination With Endocrine and Targeted 
 Therapies in Participants With Breast Cancer\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 etformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT03006172
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06064669-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT06064669)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Effect of Metformin 
 on Healthy Live Birth in Women With Prediabetes\nEstimated primary complet
 ion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT06064669
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06120881-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT06120881)
DESCRIPTION:Glucophage (metformin)\, phase 1\, Type 2 Diabetes.\nStudy: Pre
 cision Dosing of Metformin in Youth With T2D\nEstimated primary completion
 : 31 December 2026. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 etformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06120881
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07165158-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07165158)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: The
  Effect of Semaglutide on Bone Health\nEstimated primary completion: 31 De
 cember 2026. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 165158
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05041907-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05041907)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Finding Treatments fo
 r COVID-19: A Trial of Antiviral Pharmacodynamics in Early Symptomatic COV
 ID-19 (PLATCOV)\nEstimated primary completion: January 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT05041907
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06611501-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06611501)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Glycemic Regulation a
 s Endometriosis Adjunct Treatment\nEstimated primary completion: January 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06611501
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07779811-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270115
DTEND;VALUE=DATE:20270116
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07779811)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Topical Metformin Ver
 sus Triple Regimen for Epidermal Melasma\nEstimated primary completion: 15
  January 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metfor
 min#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07779811
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07024823-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07024823)
DESCRIPTION:Glucophage (metformin)\, phase 1\, Type 2 Diabetes.\nStudy: A S
 tudy to Investigate Safety\, Tolerability\, PK\, and PD of AZD4248 in Heal
 thy Participants\, Participants With CKD and Type 2 Diabetes\, Assess Home
  Measurements of Creatinine in a Non-Interventional Cohort\, and Assess th
 e Effect of AZD4248 on the PK of Midazolam and Metformin in Healthy Partic
 ipants\nEstimated primary completion: 29 January 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07024823
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05205317-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270130
DTEND;VALUE=DATE:20270131
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT05205317)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Comparison of the Th
 erapeutic Effects of VR and VR + Metformin in the Treatment of Cesarean Se
 ction Scar Defect\nEstimated primary completion: 30 January 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05205317
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04578652-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04578652)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Fiber and Metformin C
 ombination Therapy in Adolescents With Severe Obesity and Insulin Resistan
 ce\nEstimated primary completion: February 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04578652
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06965868-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT06965868)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Role of the Blood-Br
 ain Barrier in Stress Resilience: Investigating New Pathways Towards Pharm
 acological Augmentation of Stress Resilience\nEstimated primary completion
 : February 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metf
 ormin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT06965868
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06377696-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06377696)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Remote Cognitive Asse
 ssment and Wearable Device While Assessing the Impact of Metformin in Pati
 ents With History of Cranial Radiation Therapy\nEstimated primary completi
 on: 1 February 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT06377696
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07806019-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07806019)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Metformin in Parkinso
 n's Disease: Safety and Efficacy\nEstimated primary completion: 1 February
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07806019
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07753317-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270207
DTEND;VALUE=DATE:20270208
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07753317)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Clinical and Radiogr
 aphic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate 
 Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM\nE
 stimated primary completion: 7 February 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07753317
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02969798-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT02969798)
DESCRIPTION:Glucophage (metformin)\, phase na\, Type 2 Diabetes.\nStudy: Pr
 e-diabetes in Subject With Impaired Fasting Glucose (IFG) and Impaired Glu
 cose Tolerance (IGT)\nEstimated primary completion: 28 February 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT02969798
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05132439-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05132439)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: MetfOrmin BenefIts Lo
 wer Extremities With Intermittent Claudication\nEstimated primary completi
 on: 28 February 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT05132439
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05893225-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05893225)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin Add-on Clin
 ical Study in Multiple Sclerosis to Evaluate Brain Remyelination And Neuro
 degeneration\nEstimated primary completion: 28 February 2027. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT05893225
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04121468-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT04121468)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: A Phase I Double Bl
 ind Study of Metformin Acting on Endogenous Neural Progenitor Cells in Chi
 ldren and Young Adults With Multiple Sclerosis\nEstimated primary completi
 on: March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metfo
 rmin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T04121468
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07339722-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07339722)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: A Study of LY4515100 
 in Healthy Participants\nEstimated primary completion: March 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07339722
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07372625-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07372625)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: A Study to Investigat
 e the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of M
 etformin\, Rosuvastatin\, Repaglinide\, and Midazolam in Patients With Adv
 anced Solid Tumors Harboring a TP53 Y220C Mutation.\nEstimated primary com
 pletion: March 2027. This is a ClinicalTrials.gov estimate\, not a confirm
 ed readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/
 metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07372625
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07873229-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07873229)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: DDI Study of ECC0509 
 With Metformin\, Midazolam\, and Caffeine\nEstimated primary completion: M
 arch 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0787
 3229
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05065372-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT05065372)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: MANATEE-T1D: Metformi
 n ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistan
 ce\, Insulin Sensitivity\, and Cardiometabolic Function in Youth With Type
  1 Diabetes\nEstimated primary completion: 1 March 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05065372
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744479-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT05744479)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Metformin for Antipsy
 chotic-induced Weight Gain in Adults With Intellectual Disability\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT05744479
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07497568-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07497568)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Effect of Local Appl
 ication of 1% Metformin Gel on Implant Stability and Peri-implant Bone Den
 sity: A Randomized Controlled Study\nEstimated primary completion: 9 March
  2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout dat
 e\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07497568
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939594-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270312
DTEND;VALUE=DATE:20270313
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07939594)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: An Evaluation of the 
 Potential for VH4011499 Drug-drug-interactions\nEstimated primary completi
 on: 12 March 2027. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/me
 tformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT07939594
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06687265-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270330
DTEND;VALUE=DATE:20270331
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06687265)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Effects of Metformin 
 on Hepatic Venous Pressure Gradient in Patients With Cirrhosis and Portal 
 Hypertension\nEstimated primary completion: 30 March 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT06687265
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05900466-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05900466)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin for Fibromy
 algia Symptoms (INFORM Trial)\nEstimated primary completion: 31 March 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT05900466
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07297290-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07297290)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Effect of Metformin U
 se on Weight Loss in Obese\, Non-diabetic People (MOWRI)\nEstimated primar
 y completion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07297290
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07442006-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07442006)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Gly
 cemic Variability of Combination Therapies in T2DM\nEstimated primary comp
 letion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT07442006
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06948825-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06948825)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Effectiveness Study o
 f a Lifestyle Intervention Versus Metformin in Mothers With Recent Gestati
 onal Diabetes\nEstimated primary completion: May 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT06948825
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07536620-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07536620)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin and Alveola
 r Cleft\nEstimated primary completion: 1 May 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT07536620
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05036226-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270521
DTEND;VALUE=DATE:20270522
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT05036226)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: COAST Therapy in Ad
 vanced Solid Tumors and Prostate Cancer\nEstimated primary completion: 21 
 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05036
 226
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07131384-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07131384)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Interaction Between 
 Inorganic Nitrate Supplementation and Metformin in Individuals With Predia
 betes\nEstimated primary completion: 1 June 2027. This is a ClinicalTrials
 .gov estimate\, not a confirmed readout date\, and it can move.\nDrug page
 : https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: h
 ttps://clinicaltrials.gov/study/NCT07131384
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07654179-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270611
DTEND;VALUE=DATE:20270612
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07654179)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Metformin as Adjunct
  Therapy in Depression-obesity Comorbidity: Clinical and Genetic Evaluatio
 n\nEstimated primary completion: 11 June 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07654179
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07173712-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07173712)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Reg
 imen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabe
 tes\nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07173712
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07696806-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07696806)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Microneedling-Assiste
 d Metformin\, Tranexamic Acid\, and Modified Kligman's Formula for Melasma
 \nEstimated primary completion: 30 June 2027. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07696806
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04758000-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04758000)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin as Maintena
 nce Therapy in Patients With Bone Sarcoma and High Risk of Relapse\nEstima
 ted primary completion: July 2027. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT04758000
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06446531-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT06446531)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Prevention of Progres
 sion of Prediabetes\, Obesity and CV Risk\nEstimated primary completion: J
 uly 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06446
 531
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07098299-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270707
DTEND;VALUE=DATE:20270708
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07098299)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin Combined Wi
 th Chemotherapy and/or Immunotherapy in Solid Malignancies\nEstimated prim
 ary completion: 7 July 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07098299
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05727761-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05727761)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Pioglitazone-Metformi
 n Combination Treatment for High Risk Oral Preneoplasia\nEstimated primary
  completion: 30 July 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT05727761
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760181-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270810
DTEND;VALUE=DATE:20270811
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07760181)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Efficacy and Safety O
 f Fractional Carbon Dioxide Laser Plus Topical Metformin In Treatment Of A
 canthosis Nigricans\nEstimated primary completion: 10 August 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07760181
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188740-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270830
DTEND;VALUE=DATE:20270831
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07188740)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin Inhibits DN
 MT3A Clonal Hematopoiesis in Acute Leukemia\nEstimated primary completion:
  30 August 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metf
 ormin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07188740
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07387900-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07387900)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Evaluation of the Che
 mo-preventive Effect of Combined Topical and Systemic Metformin on Oral Le
 ukoplakia\nEstimated primary completion: September 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT07387900
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07770711-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07770711)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Inositol and Metform
 in Administration in Mediterranean Diet and Low-Carbohydrate Diets in Wome
 n With PCOS\nEstimated primary completion: September 2027. This is a Clini
 calTrials.gov estimate\, not a confirmed readout date\, and it can move.\n
 Drug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07770711
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07139405-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07139405)
DESCRIPTION:Glucophage (metformin)\, phase 2\, Type 2 Diabetes.\nStudy: Tri
 Glytza®-01 Versus Metformin in Overweight and Obese Adults With Type 2 Di
 abetes and Inadequate Glycaemic Control Despite Metformin Therapy\nEstimat
 ed primary completion: 1 September 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT07139405
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04194424-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270915
DTEND;VALUE=DATE:20270916
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT04194424)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: A Multidisciplinary 
 Weight Loss Program at AUB-MC\nEstimated primary completion: 15 September 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT04194424
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04583462-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270929
DTEND;VALUE=DATE:20270930
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04583462)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Impact of Metformin o
 n Peripheral Arterial Calcification in Type 1 Diabetes\nEstimated primary 
 completion: 29 September 2027. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT04583462
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06012682-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06012682)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Clinical Trials Evalu
 ating the Effect of Metformin Treatment on Function Endometrium in Women D
 iagnosed With Idiopathic Infertility\nEstimated primary completion: 30 Sep
 tember 2027. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformi
 n#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT06
 012682
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07001878-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07001878)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Cannabis Potency Effe
 cts on Brain White Matter in Early Phase Psychosis\nEstimated primary comp
 letion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a c
 onfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio
 /drug/metformin#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07001878
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07323381-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07323381)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Eff
 ects of Henagliflozin Proline and Metformin XR on Body Composition in Geri
 atric Patients With Newly Diagnosed T2DM\nEstimated primary completion: 30
  September 2027. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metf
 ormin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07323381
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07867236-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07867236)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Osteogenic Potential
  of Topical Metformin Gel on Cystic Jaw Defects\nEstimated primary complet
 ion: 30 September 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07867236
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317806-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT05317806)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Metformin Use in Card
 iac Fibrosis in PAI-1 Deficiency\nEstimated primary completion: October 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT05317806
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06044025-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT06044025)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: A Feasibility Study E
 valuating a Role for Maintenance Therapy in Patients With Biochemically Pr
 ogressive Castration Sensitive Prostate Cancer on Intermittent Androgen De
 privation Therapy\nEstimated primary completion: October 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06044025
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07778719-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271010
DTEND;VALUE=DATE:20271011
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07778719)
DESCRIPTION:Glucophage (metformin)\, phase na\, Type 2 Diabetes.\nStudy: Me
 tformin-Dapagliflozin Effects on IGF-1 in Male T2DM With MASLD\nEstimated 
 primary completion: 10 October 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07778719
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05949008-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT05949008)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Effect of Metformin\,
  a Drug Used to Treat Diabetes\, vs Placebo\nEstimated primary completion:
  30 October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/met
 formin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT05949008
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06090227-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT06090227)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: AMPK-activation by 
 Metformin in FSGS: AMP-FSGS\nEstimated primary completion: November 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT06090227
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06924658-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271120
DTEND;VALUE=DATE:20271121
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06924658)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin in Safety a
 nd Efficacy in Gouty Patients\nEstimated primary completion: 20 November 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06924658
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05230758-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05230758)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Effect of Metformin o
 n Behaviour and the Brain in Children Treated for a Brain Tumour\nEstimate
 d primary completion: 30 November 2027. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT05230758
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04511416-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04511416)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Preventing Cognitive 
 Decline with Metformin\nEstimated primary completion: December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT04511416
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06682351-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT06682351)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Het
 erogeneity of Diabetes: Integrated Muli-Omics to Identify Physiologic Subp
 henotypes and Evaluate Targeted Prevention\nEstimated primary completion: 
 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metfor
 min#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06682351
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06463743-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06463743)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin as an add-o
 n or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
 \nEstimated primary completion: 1 December 2027. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT06463743
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07280572-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07280572)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: RECLAIM Adaptive Plat
 form Trial for PCC Treatments\nEstimated primary completion: 1 December 20
 27. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07280572
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07939750-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07939750)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Sot
 agliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in
  Type 2 Diabetes\nEstimated primary completion: 1 December 2027. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT07939750
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530383-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04530383)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin for People 
 With CFRD on CFTR Modulator Therapy to Improve Ion Channel Function\nEstim
 ated primary completion: 30 December 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT04530383
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05426044-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05426044)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin as a Neurop
 rotective Therapy for Glaucoma\nEstimated primary completion: 31 December 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05426044
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05917587-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT05917587)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin for the Tre
 atment of Microvascular Dysfunction After Gestational Diabetes\nEstimated 
 primary completion: 31 December 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT05917587
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06033131-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06033131)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: PI4 - A Trial Assessi
 ng Metformin to Prolong Gestation in Preterm Preeclampsia\nEstimated prima
 ry completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT06033131
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07045142-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07045142)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin Alleviates 
 Abnormal Glucose Metabolism Induced by Statins in Schizophrenia Patients\n
 Estimated primary completion: 31 December 2027. This is a ClinicalTrials.g
 ov estimate\, not a confirmed readout date\, and it can move.\nDrug page: 
 https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: htt
 ps://clinicaltrials.gov/study/NCT07045142
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120815-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07120815)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Optimizing Metformin 
 Use in Polycystic Ovary Syndrome\nEstimated primary completion: 31 Decembe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0712081
 5
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07244003-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07244003)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: Eff
 icacy and Safety of the Met+SGLT-2i+GLP-1RA in Patients With Type 2 Diabet
 es With Poor Glycemic Control\nEstimated primary completion: 31 December 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07244003
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07460336-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07460336)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Effects of Cofroglip
 tin on Beta-Cell Function in LADA Patients\nEstimated primary completion: 
 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/met
 formin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07460336
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07588932-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07588932)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Relying on Pharmacoth
 erapy to Improve Motor Gains in Chronic Stroke Survivors\nEstimated primar
 y completion: 31 December 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07588932
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07771010-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT07771010)
DESCRIPTION:Glucophage (metformin)\, phase 4\, Type 2 Diabetes.\nStudy: The
  Effect of Empagliflozin and Metformin on Oxidative Capacity and Microvasc
 ular Reactivity of Skeletal Muscle in Patients With Type 2 Diabetes Mellit
 us\nEstimated primary completion: 31 December 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07771010
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06429007-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280101
DTEND;VALUE=DATE:20280102
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT06429007)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: A Safety and Feasibil
 ity Trial Protocol of Metformin in Infants After Perinatal Brain Injury\nE
 stimated primary completion: 1 January 2028. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT06429007
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03311308-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT03311308)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: A Trial of Pembrolizu
 mab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma\nEstimat
 ed primary completion: 31 January 2028. This is a ClinicalTrials.gov estim
 ate\, not a confirmed readout date\, and it can move.\nDrug page: https://
 assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT03311308
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05468554-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT05468554)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Evaluation of Metform
 in Effect on the Fertility of Women Treated With 131I for Thyroid Cancer\n
 Estimated primary completion: 31 January 2028. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05468554
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07693452-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07693452)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin in Pseudomy
 xoma Peritonei Secondary to Appendiceal Mucinous Neoplasms\nEstimated prim
 ary completion: February 2028. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07693452
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07768280-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07768280)
DESCRIPTION:Glucophage (metformin)\, phase na\, Type 2 Diabetes.\nStudy: Ef
 ficacy and Safety of Hebenrun in Patients With Type 2 Diabetes\nEstimated 
 primary completion: February 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT07768280
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04545736-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280202
DTEND;VALUE=DATE:20280203
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT04545736)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: Oral Metformin for 
 Treatment of ABCA4 Retinopathy\nEstimated primary completion: 2 February 2
 028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT04545736
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04530058-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280331
DTEND;VALUE=DATE:20280401
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04530058)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: The Effects of Metfor
 min on Morbidity and Mortality in Elderly Patients\nEstimated primary comp
 letion: March 2028. This is a ClinicalTrials.gov estimate\, not a confirme
 d readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/m
 etformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04530058
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07065591-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280417
DTEND;VALUE=DATE:20280418
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07065591)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Anti-Diabetic Drug\, 
 Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity\
 nEstimated primary completion: 17 April 2028. This is a ClinicalTrials.gov
  estimate\, not a confirmed readout date\, and it can move.\nDrug page: ht
 tps://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07065591
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07226453-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07226453)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Target Validation and
  Efficacy of Metformin in Patients With Posterior Fossa Group A (PFA) Epen
 dymoma\nEstimated primary completion: 30 April 2028. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07226453
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04945148-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280531
DTEND;VALUE=DATE:20280601
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04945148)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Oxidative Phosphoryla
 tion Targeting In Malignant Glioma Using Metformin Plus Radiotherapy Temoz
 olomide\nEstimated primary completion: May 2028. This is a ClinicalTrials.
 gov estimate\, not a confirmed readout date\, and it can move.\nDrug page:
  https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT04945148
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07568574-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280501
DTEND;VALUE=DATE:20280502
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07568574)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Impact of Medically 
 Supervised Performance-Enhancing Substances (PES) on Elite Athletes\nEstim
 ated primary completion: 1 May 2028. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinic
 altrials.gov/study/NCT07568574
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04500756-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04500756)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Limiting AAA With Met
 formin (LIMIT) Trial\nEstimated primary completion: 30 June 2028. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04500756
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05109169-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT05109169)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: METformin and FINGER 
 Intervention to Prevent Cognitive Impairment and Disability in Older Adult
 s at Risk for Dementia\nEstimated primary completion: 30 June 2028. This i
 s a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it ca
 n move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05109169
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07666698-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT07666698)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: A Study of Metformi
 n to Improve Cardiac Function After LVAD Implantation\nEstimated primary c
 ompletion: July 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07666698
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03675893-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280801
DTEND;VALUE=DATE:20280802
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT03675893)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: RESOLVE: Abemaciclib 
 + Letrozole +/- Metformin or Gedatolisib in Endometrial Cancer\nEstimated 
 primary completion: 1 August 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinical
 trials.gov/study/NCT03675893
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07120971-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07120971)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin for Prematu
 re Infants With Bronchopulmonary Dysplasia\nEstimated primary completion: 
 1 September 2028. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/met
 formin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT07120971
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07815808-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07815808)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Cardioprotective Effe
 ct of Empagliflozin in Breast Cancer Patients\nEstimated primary completio
 n: 30 September 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/st
 udy/NCT07815808
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07291297-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20281031
DTEND;VALUE=DATE:20281101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07291297)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Metformin Hydrochlori
 de in Combination With Standard of Care Systemic Therapy in Previously Unt
 reated Advanced Unresectable or Metastatic Soft Tissue Sarcoma\nEstimated 
 primary completion: October 2028. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/metformin#upcoming-events\nRegistry record: https://clinicalt
 rials.gov/study/NCT07291297
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06829238-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT06829238)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Assessment of Metform
 in for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With
  a History of Injection Drug Use\nEstimated primary completion: 30 Novembe
 r 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upc
 oming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0682923
 8
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07898839-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07898839)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: FEAST and HOPE: Redox
  PSC Pilot Study\nEstimated primary completion: December 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07898839
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06030622-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT06030622)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: Phase 2A Pilot C3 T
 rial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer\nEstima
 ted primary completion: 1 December 2028. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06030622
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07890064-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT07890064)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Canagliflozin Plus Pr
 ogestin for Atypical Endometrial Hyperplasia and Early-Stage Endometrial C
 ancer\nEstimated primary completion: 1 January 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07890064
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07275359-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290201
DTEND;VALUE=DATE:20290202
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07275359)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Investigating Senolyt
 ic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbati
 ons\nEstimated primary completion: 1 February 2029. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07275359
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07520110-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290315
DTEND;VALUE=DATE:20290316
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07520110)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin to Attenuat
 e Progressive Respiratory Decline in Idiopathic Pulmonary Fibrosis\nEstima
 ted primary completion: 15 March 2029. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07520110
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06452498-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290319
DTEND;VALUE=DATE:20290320
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06452498)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Preeclampsia Interven
 tion Netherlands\nEstimated primary completion: 19 March 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06452498
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07589387-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290430
DTEND;VALUE=DATE:20290501
SUMMARY:Glucophage (metformin): Phase na readout est. (NCT07589387)
DESCRIPTION:Glucophage (metformin)\, phase na.\nStudy: Hypertension Treatme
 nt in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3\nE
 stimated primary completion: 30 April 2029. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https:/
 /clinicaltrials.gov/study/NCT07589387
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06999343-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290501
DTEND;VALUE=DATE:20290502
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06999343)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Exploring the Anti-ag
 eing Effects of Metformin in COPD\nEstimated primary completion: 1 May 202
 9. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT06999343
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742710-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT06742710)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Liraglutide Treatment
  in Obese Infertile PCOS Women\nEstimated primary completion: 30 May 2029.
  This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, an
 d it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06742710
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06185179-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT06185179)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin and Muscle 
 Recovery\nEstimated primary completion: 31 May 2029. This is a ClinicalTri
 als.gov estimate\, not a confirmed readout date\, and it can move.\nDrug p
 age: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06185179
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02915198-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20290928
DTEND;VALUE=DATE:20290929
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT02915198)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: Investigation of Metf
 ormin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes\nEstimate
 d primary completion: 28 September 2029. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT02915198
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06096259-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT06096259)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Preventing Injured Kn
 ees From osteoArthritis: Severity Outcomes\nEstimated primary completion: 
 December 2029. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metfor
 min#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 06096259
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06445946-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Glucophage (metformin): Phase 4 readout est. (NCT06445946)
DESCRIPTION:Glucophage (metformin)\, phase 4.\nStudy: DECIDE: A Comparative
  Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gest
 ational Diabetes\nEstimated primary completion: December 2029. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT06445946
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05768139-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20300731
DTEND;VALUE=DATE:20300801
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT05768139)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: First-in-Human Stud
 y of Tersolisib (STX-478) as Monotherapy and in Combination With Other Ant
 ineoplastic Agents in Participants With Advanced Solid Tumors\nEstimated p
 rimary completion: July 2030. This is a ClinicalTrials.gov estimate\, not 
 a confirmed readout date\, and it can move.\nDrug page: https://assetmemo.
 bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT05768139
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07179042-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07179042)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Intertrochanteric Fem
 ur Fracture Patients Who Receive Metformin With a Placebo\nEstimated prima
 ry completion: September 2030. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/metformin#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07179042
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03424005-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20300930
DTEND;VALUE=DATE:20301001
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT03424005)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: A Study Evaluating 
 the Efficacy and Safety of Multiple Treatment Combinations in Patients Wit
 h Metastatic or Locally Advanced Breast Cancer\nEstimated primary completi
 on: 30 September 2030. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/metformin#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT03424005
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07901959-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20301014
DTEND;VALUE=DATE:20301015
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07901959)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Safety and Tolerabili
 ty of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia\nEsti
 mated primary completion: 14 October 2030. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07901959
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07899307-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20301030
DTEND;VALUE=DATE:20301031
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07899307)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin in Acute Is
 chemic Stroke\nEstimated primary completion: 30 October 2030. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07899307
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT01042379-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT01042379)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: I-SPY TRIAL: Neoadjuv
 ant and Personalized Adaptive Novel Agents to Treat Breast Cancer\nEstimat
 ed primary completion: December 2030. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/metformin#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT01042379
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04939935-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20301231
DTEND;VALUE=DATE:20310101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT04939935)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Implementation of Met
 formin theraPy to Ease Decline of Kidney Function in Polycystic Kidney Dis
 ease (IMPEDE-PKD)\nEstimated primary completion: December 2030. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT04939935
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07136987-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20310131
DTEND;VALUE=DATE:20310201
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07136987)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: A Trial of 2 Disease-
 Modifying Drugs (Metformin and N-acetylcysteine ) to Promote TB Lung Funct
 ion Recovery\nEstimated primary completion: January 2031. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07136987
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129473-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT07129473)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: Hyperemesis Gravida
 rum Risk Reduction With Metformin\nEstimated primary completion: March 203
 1. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07129473
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724132-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20310331
DTEND;VALUE=DATE:20310401
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT07724132)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: An Evaluation of Trea
 tments for Sustained Clinical Response (18 Months) in Symptomatic Alzheime
 r's Disease\nEstimated primary completion: March 2031. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry reco
 rd: https://clinicaltrials.gov/study/NCT07724132
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06763328-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20310616
DTEND;VALUE=DATE:20310617
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT06763328)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Metformin for the Tre
 atment of Insulin Resistance in Women With Stage I-III Breast Cancer Compl
 eting Chemotherapy\nEstimated primary completion: 16 June 2031. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT06763328
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07699367-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20311001
DTEND;VALUE=DATE:20311002
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT07699367)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Metformin and ACLR Mu
 scle Recovery\nEstimated primary completion: 1 October 2031. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistr
 y record: https://clinicaltrials.gov/study/NCT07699367
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04536805-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20311130
DTEND;VALUE=DATE:20311201
SUMMARY:Glucophage (metformin): Phase 1/2 readout est. (NCT04536805)
DESCRIPTION:Glucophage (metformin)\, phase 1/2.\nStudy: Relapse in Previous
 ly Irradiated Prostate Bed : Stereotactic Ablative Reirradiation Potentiat
 ed by Metformin\nEstimated primary completion: November 2031. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/metformin#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT04536805
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04114136-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20320430
DTEND;VALUE=DATE:20320501
SUMMARY:Glucophage (metformin): Phase 2 readout est. (NCT04114136)
DESCRIPTION:Glucophage (metformin)\, phase 2.\nStudy: Anti-PD-1 mAb Plus Me
 tabolic Modulator in Solid Tumor Malignancies\nEstimated primary completio
 n: 30 April 2032. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/met
 formin#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/
 NCT04114136
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05515978-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20351020
DTEND;VALUE=DATE:20351021
SUMMARY:Glucophage (metformin): Phase 1 readout est. (NCT05515978)
DESCRIPTION:Glucophage (metformin)\, phase 1.\nStudy: Pragmatic Trial of Me
 tformin for Glucose Intolerance or Increased BMI in Prostate Cancer Patien
 ts\nEstimated primary completion: 20 October 2035. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/metformin#upcoming-events\nRegistry record: 
 https://clinicaltrials.gov/study/NCT05515978
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02947503-280@assetmemo.bio
DTSTAMP:20261121T003103Z
DTSTART;VALUE=DATE:20431231
DTEND;VALUE=DATE:20440101
SUMMARY:Glucophage (metformin): Phase 3 readout est. (NCT02947503)
DESCRIPTION:Glucophage (metformin)\, phase 3.\nStudy: Pregnancy Outcomes: E
 ffects of Metformin Study (POEM Study)\nEstimated primary completion: Dece
 mber 2043. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/metformin#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0294
 7503
URL:https://assetmemo.bio/drug/metformin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
